How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance

[1]  Ze-Zhou Song Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. , 2008, International journal of cardiology.

[2]  D. Jassal,et al.  Late gadolinium enhancement cardiovascular magnetic resonance in genotyped hypertrophic cardiomyopathy with normal phenotype , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[3]  R. Nijveldt,et al.  Semi-quantitative assessment of right ventricular function in comparison to a 3D volumetric approach: A cardiovascular magnetic resonance study , 2008, European Radiology.

[4]  P. J. Griffiths,et al.  Dilated and Hypertrophic Cardiomyopathy Mutations in Troponin and &agr;-Tropomyosin Have Opposing Effects on the Calcium Affinity of Cardiac Thin Filaments , 2007, Circulation research.

[5]  L. Carrier,et al.  Cardiac Myosin-Binding Protein C Is Required for Complete Relaxation in Intact Myocytes , 2007, Circulation research.

[6]  R. Moss,et al.  Differential Roles of Cardiac Myosin-Binding Protein C and Cardiac Troponin I in the Myofibrillar Force Responses to Protein Kinase A Phosphorylation , 2007, Circulation research.

[7]  J. Bronzwaer,et al.  Effects of aging on left atrioventricular coupling and left ventricular filling assessed using cardiac magnetic resonance imaging in healthy subjects. , 2007, The American journal of cardiology.

[8]  S. Chugh,et al.  Gadolinium-enhanced magnetic resonance imaging for detection and quantification of fibrosis in human myocardium in vitro , 2007, The International Journal of Cardiovascular Imaging.

[9]  G. Vassort,et al.  Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice. , 2006, Cardiovascular research.

[10]  K. Hayashi,et al.  Differences in diagnostic value of four electrocardiographic voltage criteria for hypertrophic cardiomyopathy in a genotyped population. , 2005, The American journal of cardiology.

[11]  Olga Bondarenko,et al.  Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  J. Seidman,et al.  Effect of Cardiac Myosin Binding Protein-C on Mechanoenergetics in Mouse Myocardium , 2004, Circulation research.

[13]  R M Heethaar,et al.  Timing of cardiac contraction in humans mapped by high-temporal-resolution MRI tagging: early onset and late peak of shortening in lateral wall. , 2004, American journal of physiology. Heart and circulatory physiology.

[14]  V. Regitz-Zagrosek,et al.  The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. , 2003, European heart journal.

[15]  M. Quiñones,et al.  Tissue Doppler Imaging Predicts the Development of Hypertrophic Cardiomyopathy in Subjects With Subclinical Disease , 2003, Circulation.

[16]  H. Smeets,et al.  Variable clinical manifestation of a novel missense mutation in the alpha-tropomyosin (TPM1) gene in familial hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[17]  S. Plein,et al.  Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady‐state free precession imaging sequences , 2003, Journal of magnetic resonance imaging : JMRI.

[18]  S. Solomon,et al.  Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic Cardiomyopathy , 2002, Circulation.

[19]  B. Maron Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[20]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[21]  M. Quiñones,et al.  Tissue Doppler Imaging Consistently Detects Myocardial Abnormalities in Patients With Hypertrophic Cardiomyopathy and Provides a Novel Means for an Early Diagnosis Before and Independently of Hypertrophy , 2001, Circulation.

[22]  James O. Mudd,et al.  An abnormal Ca2+ response in mutant sarcomere protein–mediated familial hypertrophic cardiomyopathy , 2000 .

[23]  A. Marian Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy , 2000, The Lancet.

[24]  O. Simonetti,et al.  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. , 1999, Circulation.

[25]  Frederick J. Schoen,et al.  A Mouse Model of Familial Hypertrophic Cardiomyopathy , 1996, Science.

[26]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[27]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[28]  A E Becker,et al.  Left ventricular fibre architecture in man. , 1981, British heart journal.

[29]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[30]  F. T. ten Cate,et al.  Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. , 2009, JACC. Cardiovascular imaging.

[31]  P. Chase,et al.  Computational simulation of hypertrophic cardiomyopathy mutations in troponin I: influence of increased myofilament calcium sensitivity on isometric force, ATPase and [Ca2+]i. , 2007, Journal of biomechanics.

[32]  James O. Mudd,et al.  An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. , 2000, The Journal of clinical investigation.